BRWA
ADMS

B. Riley Wealth Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

B. Riley Wealth Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,400
Closed -$1.01M – 756
2018
Q3 		$1.01M Buy
50,400
+100
+0.2% +$2.35K 0.12% 189
2018
Q2 		$1.3M Sell
50,300
-19,400
-28% -$537K 0.17% 144
2018
Q1 		$1.67M Buy
69,700
+31,000
+80% +$977K 0.23% 106
2017
Q4 		$1.31M Buy
+38,700
New +$1.08M 0.18% 143

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

B. Riley Wealth Advisors's ADMS Position: Q4 2018 in Review

B. Riley Wealth Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 50,400 shares — an estimated $1.01M sold.

B. Riley Wealth Advisors first reported a position in ADMS in Q4 2017 and held it in 4 quarters. The position peaked at $1.67M in Q1 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • B. Riley Wealth Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 50,400 Adamas Pharmaceuticals shares in Q4 2018, an estimated $1.01M.
  • B. Riley Wealth Advisors first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • B. Riley Wealth Advisors's Adamas Pharmaceuticals position peaked at $1.67M in Q1 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2018, filed 8 Feb 2019.